|
|
Clover Health Investments Corp (NASDAQ: CLOV) |
|
Price: $3.7000
$0.04 
1.093%
|
| Day's High:
| $3.74
| Week Perf:
| 10.12 %
|
| Day's Low: |
$ 3.56 |
30 Day Perf: |
-18.5 % |
| Volume (M): |
3,972 |
52 Wk High: |
$ 4.87 |
| Volume (M$): |
$ 14,698 |
52 Wk Avg: |
$2.58 |
| Open: |
$3.66 |
52 Wk Low: |
$0.61 |
|
|
| Market Capitalization (Millions $) |
1,768 |
| Shares
Outstanding (Millions) |
478 |
| Employees |
552 |
| Revenues (TTM) (Millions $) |
1,371 |
| Net Income (TTM) (Millions $) |
-43 |
| Cash Flow (TTM) (Millions $) |
18 |
| Capital Exp. (TTM) (Millions $) |
2 |
Clover Health Investments Corp
Clover Health Investments Corp is a healthcare company that specializes in Medicare Advantage plans. The company was founded in 2014 by Vivek Garipalli and Kris Gale, with the aim of using technology to improve healthcare outcomes for seniors.
Clover Health has a unique approach to healthcare that leverages data analytics and machine learning algorithms to identify patients that may require additional care, and proactively intervenes to prevent health issues from developing. Clover Health's focus on preventative care and disease management has allowed the company to deliver better healthcare outcomes at a lower cost than traditional Medicare plans.
Clover Health's Medicare Advantage plans offer a range of benefits, including hospitalization, doctor visits, lab tests, and prescription drugs. The plans also include additional benefits such as vision, dental, and hearing coverage, as well as fitness and wellness programs.
In 2021, Clover Health went public through a merger with a special purpose acquisition company (SPAC) called Social Capital Hedosophia Holdings Corp III. The company trades on the NASDAQ under the ticker symbol CLOV.
Clover Health has faced some criticism in recent years, particularly around allegations of fraud and misleading marketing practices. The company has also come under scrutiny for its relationship with its largest investor, venture capital firm Chamath Palihapitiya.
Despite these issues, Clover Health remains a significant player in the Medicare Advantage market, with a growing customer base and a commitment to improving healthcare outcomes for seniors through the use of technology and innovation.
Company Address: 3401 Mallory Lane Franklin 37067 TN
Company Phone Number: 432-2133 Stock Exchange / Ticker: NASDAQ CLOV
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Product Service News
Published Thu, Oct 10 2024 9:04 PM UTC
Clover Health?s Impressive 4-Star Triumph: A Beacon of Quality in Medicare Advantage Plans In a remarkable display of operational excellence, Clover Health Investments Corp has achieved a prestigious 4-star rating for its PPO Medicare Advantage Plans for the year 2025. This accolade signifies an exceptional performance across multiple measures of healthcare quality, includin...
|
| Contract
Published Tue, Sep 3 2024 8:05 PM UTC
In a move that underscores the ongoing transformation of the healthcare landscape through technology, Counterpart Health, Inc. has announced a significant multi-year agreement with The Iowa Clinic, one of the most respected multispecialty healthcare groups in the United States. This partnership, revealed on September 3, 2024, signals Counterpart s intent to deploy its AI-pow...
|
| Stock Market Announcement
Published Fri, Jun 14 2024 1:00 PM UTC
In a recent press release, Clover Health Investments Corp announced that CMS has recalculated the star rating for its PPO plans, increasing it from 3.0 Stars to 3.5 Stars for the 2025 payment year. This news comes as a significant improvement for the company and its shareholders, as it has the potential to have a positive impact on its financial performance moving forwa...
|
| Product Service News
Published Wed, May 29 2024 12:01 PM UTC
Clover Health Unveils Counterpart Health: Revolutionizing Medicare Advantage with Data-Driven Technology FRANKLIN, Tenn., May 29, 2024 - In a transformative leap for the healthcare industry, Clover Health Investments, Corp. (NASDAQ: CLOV) today announced the launch of Counterpart Health, a pioneering SaaS and tech-enabled services solution designed to extend the capabiliti...
|
| Clover Health Investments Corp
Clover Health Investments Corp (NASDAQ: CLOV) has exhibited concerning financial performance in the first quarter of 2024. Despite a slight improvement in earnings per share and a decrease in the loss per share compared to the previous year, the overall revenue of the company has declined significantly. Additionally, recent executive appointments and stock unit awards may not be sufficient to offset the challenges faced by Clover Health in the highly competitive healthcare industry. This bearish article delves into the company's financials, recent announcements, and potential implications for its future results.
Deteriorating Revenue and Financial Performance:
During the January to March 31, 2024 interval, Clover Health reported a revenue decline of 34.267% compared to the same quarter last year, and a sequential revenue drop of 32.01% from the preceding quarter. These figures stand in stark contrast to the top-line improvement witnessed across the Accident & Health Insurance industry during the same period. The deteriorating revenue trend raises concerns about Clover Health's ability to generate sustainable growth and remain competitive.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.1 $ |
| Revenues (TTM) |
2.87 $
|
| Cash Flow (TTM) |
0.04 $ |
| Cash |
0.06 $
|
| Book Value |
0.71 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.1 $
|
| Revenues (TTM) |
2.87 $ |
| Cash Flow (TTM) |
0.04 $ |
| Cash |
0.06 $
|
| Book Value |
0.71 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Insurance |
|
 1.3 % |
of total Revenue |
| Corporate Other |
|
9.8 % |
of total Revenue |
| Interrevenues |
|
14.18 % |
of total Revenue |
| Eliminations |
|
-8.56 % |
of total Revenue |
| |
On March 12 2024 the Clover Health Investments provided following guidance
Clover Health Investments Corp announced its financial results for the fourth quarter and full year of 2023. The company reported a significant improvement in its Insurance Medical Cost Ratio (MCR), with full-year 2023 MCR coming in at 81.2% and fourth quarter MCR at 82.4%. This improvement demonstrates the company's continued momentum in its financial performance.
Looking ahead to 2024, Clover Health Investments Corp provided guidance for the full year. The company is optimistic about its prospects and anticipates further growth and success in the coming year. With the positive trend in MCR and other financial indicators, Clover Health Investments Corp is well-positioned for continued success in the ...
|
|
|
2.07% 